178 related articles for article (PubMed ID: 36472561)
1. Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
Xie X; Zheng YG; Chen H; Li J; Luo RH; Chen L; Zheng CB; Zhang S; Peng P; Ma D; Yang LM; Zheng YT; Liu H; Wang J
J Med Chem; 2022 Dec; 65(24):16526-16540. PubMed ID: 36472561
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
[TBL] [Abstract][Full Text] [Related]
3. CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.
Kang Y; Wu Z; Lau TC; Lu X; Liu L; Cheung AK; Tan Z; Ng J; Liang J; Wang H; Li S; Zheng B; Li B; Chen L; Chen Z
J Biol Chem; 2012 May; 287(20):16499-509. PubMed ID: 22447925
[TBL] [Abstract][Full Text] [Related]
4. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
[TBL] [Abstract][Full Text] [Related]
5. Computational study on the interaction between CCR5 and HIV-1 entry inhibitor maraviroc: insight from accelerated molecular dynamics simulation and free energy calculation.
Bai Q; Zhang Y; Li X; Chen W; Liu H; Yao X
Phys Chem Chem Phys; 2014 Nov; 16(44):24332-8. PubMed ID: 25296959
[TBL] [Abstract][Full Text] [Related]
6. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
Lieberman-Blum SS; Fung HB; Bandres JC
Clin Ther; 2008 Jul; 30(7):1228-50. PubMed ID: 18691983
[TBL] [Abstract][Full Text] [Related]
7. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
Westby M; Lewis M; Whitcomb J; Youle M; Pozniak AL; James IT; Jenkins TM; Perros M; van der Ryst E
J Virol; 2006 May; 80(10):4909-20. PubMed ID: 16641282
[TBL] [Abstract][Full Text] [Related]
8. CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.
Kim MB; Giesler KE; Tahirovic YA; Truax VM; Liotta DC; Wilson LJ
Expert Opin Investig Drugs; 2016 Dec; 25(12):1377-1392. PubMed ID: 27791451
[TBL] [Abstract][Full Text] [Related]
9. Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications.
Xu GG; Guo J; Wu Y
Curr Top Med Chem; 2014; 14(13):1504-14. PubMed ID: 25159165
[TBL] [Abstract][Full Text] [Related]
10. Structure-based identification of novel scaffolds as potential HIV-1 entry inhibitors involving CCR5.
Appiah-Kubi P; Iwuchukwu EA; Soliman MES
J Biomol Struct Dyn; 2022; 40(23):13115-13126. PubMed ID: 34569417
[TBL] [Abstract][Full Text] [Related]
11. Preclinical discovery and development of maraviroc for the treatment of HIV.
Veljkovic N; Vucicevic J; Tassini S; Glisic S; Veljkovic V; Radi M
Expert Opin Drug Discov; 2015 Jun; 10(6):671-84. PubMed ID: 25927601
[TBL] [Abstract][Full Text] [Related]
12. CCR5 antagonism in HIV infection: current concepts and future opportunities.
Wilkin TJ; Gulick RM
Annu Rev Med; 2012; 63():81-93. PubMed ID: 22034870
[TBL] [Abstract][Full Text] [Related]
13. Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.
Lobritz MA; Ratcliff AN; Marozsan AJ; Dudley DM; Tilton JC; Arts EJ
Antimicrob Agents Chemother; 2013 Jun; 57(6):2640-50. PubMed ID: 23529732
[TBL] [Abstract][Full Text] [Related]
14. Targeting CCR5 for anti-HIV research.
Gu WG; Chen XQ
Eur J Clin Microbiol Infect Dis; 2014 Nov; 33(11):1881-7. PubMed ID: 25027072
[TBL] [Abstract][Full Text] [Related]
15. Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
Jiang X; Feyertag F; Meehan CJ; McCormack GP; Travers SA; Craig C; Westby M; Lewis M; Robertson DL
J Virol; 2015 Nov; 89(22):11457-72. PubMed ID: 26339063
[TBL] [Abstract][Full Text] [Related]
16. Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.
Visseaux B; Charpentier C; Collin G; Bertine M; Peytavin G; Damond F; Matheron S; Lefebvre E; Brun-Vézinet F; Descamps D;
PLoS One; 2015; 10(8):e0134904. PubMed ID: 26247470
[TBL] [Abstract][Full Text] [Related]
17. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.
Yost R; Pasquale TR; Sahloff EG
Am J Health Syst Pharm; 2009 Apr; 66(8):715-26. PubMed ID: 19336831
[TBL] [Abstract][Full Text] [Related]
18. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
Hunt JS; Romanelli F
Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
[TBL] [Abstract][Full Text] [Related]
19. Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s.
Nakata H; Maeda K; Das D; Chang SB; Matsuda K; Rao KV; Harada S; Yoshimura K; Ghosh AK; Mitsuya H
Sci Rep; 2019 Mar; 9(1):4828. PubMed ID: 30886166
[TBL] [Abstract][Full Text] [Related]
20. Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
Peng P; Chen H; Zhu Y; Wang Z; Li J; Luo RH; Wang J; Chen L; Yang LM; Jiang H; Xie X; Wu B; Zheng YT; Liu H
J Med Chem; 2018 Nov; 61(21):9621-9636. PubMed ID: 30234300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
